Orlistat is a drug, used to treat Obesity by inhibiting pancreatic lipase enzyme. It is highly lipophilic having bioavailability of less than 1%. Self-microemulsifying drug delivery system (SMEDDS), being lipid based formulation can its increase the bioavailability. Hence, Orlistat SMEDDS were formulated having increased solubility, dissolution rate and therapeutic efficacy.

Materials and Methods {#sec1-1}
=====================

Orlistat was procured from Centurion Laboratories, Vadodara. Propylene glycol monocaprylate, Propylene glycol laurate and Caprylic triglyceride were obtained from Gattefosse. Cremophor Rh 40, Poly ethylene glycol (PEG) 400, Propylene glycol and Polysorbate 80 were obtained from Sigma-Aldrich, Mumbai. Propylene glycol caprylocaprate, Glyceryl tricaprylate, Glyceryl monocaprylate and Decaglycerol Decaolate were obtained from Abitec Corporation. Propylene glycol was obtained from shivam industries, Mumbai. All other chemicals and solvents were of analytical grade.

Solubility studies {#sec2-1}
------------------

The equilibrium solubility of Orlistat in various oils, surfactants and co-surfactants was determined by adding excess orlistat to various vials in vehicle.

Construction of pseudoternary phase diagram {#sec2-2}
-------------------------------------------

Different Pseudo-ternary phase diagram of oil (Propylene glycol monocaprylate), surfactant (Propylene glycol laurate), co-surfactant (Polysorbate 80) and water were developed using titration method at 25±2°C.

Preparation of Orlistat SMEDDS {#sec2-3}
------------------------------

Orlistat containing oil solution was added in the surfactant system solution with continuous stirring and vortex mixing until homogenous mixture is formed.

Particle size distribution (PSD) and ζ-potential analysis {#sec2-4}
---------------------------------------------------------

It was studied by Malvern Metasizer.

Thermodynamic stability {#sec2-5}
-----------------------

Orlistat SMEDDS were diluted with an aqueous medium and centrifuged at 3500 rpm for 30 min and formulations were observed visually for phase separation. Formulations were subjected to freeze thaw cycles (--20°C for 2 days followed by +40°C for 2 days).

Dispersibility test {#sec2-6}
-------------------

It was assessed in standard USP XXII dissolution apparatus 2 by dispersing the formulation in 900 ml of deinonized water and 0.1 N HCl at 37±0.5°C, 50 RPM.

*In vitro* drug release {#sec2-7}
-----------------------

It was carried out in 900 ml of 3% SLS in 0.5% NaCl, pH 6.0. Liquid SMEDDS were filled in hard gelatin capsule and commercial form and plain drug were taken.

HPLC method {#sec2-8}
-----------

C~18~ column (250×4.6 mm) with 5 μm particle size was taken. The mobile phase consisted of orthophosphoric acid 0.1%-acetonitrile (10:90 v/v).

Stability studies {#sec2-9}
-----------------

Formulations which were found to be thermodynamically stable were subjected to stability studies in empty hard gelatin capsule size "O" at 25°C±2°C/60±5% RH, 35°C±2°C/65±5% RH and 40°C±2°C/75±5% RH.

Results and Discussion {#sec1-2}
======================

Propylene glycol laurate and Propylene glycol monocaprylate followed by Polysorbate 80 showed the highest solubilization capacity for orlistat so they were selected as oil, surfactant and co-surfactant respectively. The region of microemulsion existence for Propylene glycol monocaprylate -- Propylene glycol laurate+polysorbate 80-water was determined by pseudoternary plot. The microemulsion area increased as the S/Cos ratio increased upto 2:1 so this ratio was selected for formulation study. Four different formulations OS-A, B, C and D based on this study was selected. The formulation OS-C had lowest particle size of 15.47nm with an average Zeta potential of --8.95 mV. During thermodynamic stability studies, the centrifugation test was cleared by all formulations but, OS-D did not pass freeze thaw cycle study. Hence, OS-D was dropped for further studies. Further, OS-A and OS-D did not pass the dispersibility test. Improved *in-vitro* drug release of Orlistat was observed in SMEDDS formulation as compared to marketed formulation and free drug. During stability studies, physical parameters like homogeneity and clarity were examined during which OS-B formulation was found to be unstable while OS-C formulation was found physically stable. Hence, Chemical stability was examined for formulation OS-C. There was no decrease in drug content found at the end of stability studies indicating that the formulation OS-C remained chemically stable. Furthermore, there were no sign of capsule shell deformations or capsule leaks indicating that formulation was compatible with the hard gelatin capsule shells.

Conclusion {#sec1-3}
==========

An optimized orlistat loaded SMEDDS formulation consisting orlistat (7.9% w/w), Propylene glycol monocaprylate (18.42% w/w), Propylene glycol laurate (49.21% w/w) and Polysorbate 80 (24.47% w/w) was successfully developed. It offers increased solubility, increased dissolution rate resulting in increased bioavailability of orlistat in comparision with the conventional oral formulation of orlistat. Results further conclude that SMEDDS formulation of lipophilic drug like orlistat has potential for increased bioavailability and can be explored as good alternative to conventional formulations.\[[@ref1][@ref2]\]
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